Optimal molecular-targeted therapies as first-line treatment for RAS wild-type, right-sided metastatic colorectal cancer from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

被引：0
|
作者：
Yamazaki, Kentaro
Takeda, Yuriko
Misumi, Toshihiro
Suzuki, Motoko
Wakabayashi, Masashi
Bando, Hideaki
Oki, Eiji
Douillard, Jean-Yves
Punt, Cornelis J. A.
Van Cutsem, Eric
Bokemeyer, Carsten
Venook, Alan P.
Maehara, Yoshihiko
Heinemann, Volker
Cremolini, Chiara
Nakayama, Goro
Andre, Thierry
Shi, Qian
De Gramont, Aimery
Yoshino, Takayuki
机构：
[1] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[2] Natl Canc Ctr Hosp East, Dept Data Sci, Kashiwa, Chiba, Japan
[3] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[4] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Japan
[5] Univ Nantes, Med Sch Nantes, Nantes, France
[6] Univ Med Ctr Utrecht, Utrecht, Netherlands
[7] Univ Hosp Gasthuisberg Leuven, Dept Gastroenterol Digest Oncol, Leuven, Belgium
[8] Katholieke Univ Leuven, Leuven, Belgium
[9] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol, Hamburg, Germany
[10] Univ Med Ctr Hamburg Eppendorf, Bone Marrow Transplantat Sect Pneumol, Hamburg, Germany
[11] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[12] Kyushu Cent Hosp, Mutual Aid Assoc Publ Sch, Fukuoka, Japan
[13] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 3, Munich, Germany
[14] Univ Hosp Pisa, Dept Oncol, Pisa, Italy
[15] Nagoya Univ, Dept Surg Gastroenterol, Grad Sch Med, Nagoya, Aichi, Japan
[16] Hop St Antoine, Paris, France
[17] Mayo Clin, Dept Quantitat Sci Res, Rochester, MN USA
[18] Franco British Hosp, Dept Med Oncol, Levallois Perret, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3588
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials
    You, Xia-Hong
    Jiang, Yu-Huan
    Fang, Zhou
    Sun, Fan
    Li, Yao
    Wang, Wei
    Xia, Zi-Jin
    Wang, Xiao-Zhong
    Ying, Hou-Qun
    ESMO OPEN, 2020, 5 (02)
  • [32] First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Bobo Zheng
    Xin Wang
    Mingtian Wei
    Quan Wang
    Jiang Li
    Liang Bi
    Xiangbing Deng
    Ziqiang Wang
    BMC Cancer, 19
  • [33] First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Zheng, Bobo
    Wang, Xin
    Wei, Mingtian
    Wang, Quan
    Li, Jiang
    Bi, Liang
    Deng, Xiangbing
    Wang, Ziqiang
    BMC CANCER, 2019, 19 (1)
  • [34] Comparison of cetuximab every 2 weeks versus standard once-weekly administration for the first-line treatment of RAS wild-type metastatic colorectal cancer among patients with left- and right-sided primary tumor location
    Kasper, S.
    Cheng, A-L.
    Rouyer, M.
    Foch, C.
    Lamy, F-X.
    Esser, R.
    Batech, M.
    Wong, C. M. J.
    Zhang, A.
    Brodowicz, T.
    Zielinski, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S542 - S543
  • [35] Characteristics of patients (pts) and prognostic factors across treatment lines (TL) in metastatic colorectal cancer (mCRC): An analysis from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
    Bachet, Jean-Baptiste
    Chibaudel, Benoist
    Rakez, Manel
    Goldberg, Richard M.
    Tebbutt, Niall C.
    Van Cutsem, Eric
    Haller, Daniel G.
    Hecht, J. Randolph Randolph
    Mayer, Robert J.
    Lichtman, Stuart M.
    Benson, Al
    Sobrero, Alberto F.
    Tabernero, Josep
    Adams, Richard
    Zalcberg, John Raymond
    Grothey, Axel
    Yoshino, Takayuki
    Shi, Qian
    De Gramont, Aimery
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Chronologic improvement in survival of first-line oxaliplatin based chemotherapy plus targeted therapy for metastatic colorectal cancer (mCRC): Analysis of the ARCAD database
    Takeda, Y.
    Yamazaki, K.
    Saltz, L.
    Douillard, J-Y.
    Punt, C. J. A.
    Van Cutsem, E.
    Bokemeyer, C.
    Venook, A.
    Koopman, M.
    Heinemann, V.
    Cremolini, C.
    Hecht, J. R.
    Schmoll, H. J. E-V.
    Nakayama, G.
    Sugihara, K.
    Oki, E.
    Andre, T.
    Shi, Q.
    De Gramont, A.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S38 - S38
  • [37] Adverse event management costs for first-line treatment with cetuximab or panitumumab of RAS wild-type metastatic colorectal cancer patients in Latin America
    Pescott, Chris
    Kasle, Adam
    Esteso, Federico
    Stefani, Stephen
    Brust, Leandro
    Pinto, Jose
    Tilli, Malena
    Massello, Matthew
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [38] Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial
    Wang, Huijuan
    Huang, Lingfei
    Gao, Peng
    Zhu, Zhengyi
    Ye, Weifeng
    Ding, Haiying
    Fang, Luo
    BMJ OPEN, 2020, 10 (02):
  • [39] Optimal Sequence and Second-Line Systemic Treatment of Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Meta-Analysis
    Wu, Chih-Chien
    Hsu, Chao-Wen
    Hsieh, Meng-Che
    Wang, Jui-Ho
    Chang, Min-Chi
    Yang, Ching-Shiang
    Su, Yi-Chia
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (21)
  • [40] Overall survival with cetuximab every 2 weeks vs standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumor location
    Kasper, S.
    Cheng, A.
    Rouyer, M.
    Foch, C.
    Lamy, F.
    Esser, R.
    Batech, M.
    Wong, C.
    Zhang, A.
    Brodowicz, T.
    Zielinski, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S114 - S114
12345